Table 1:
Demographics of patients with DIBSG included in this study
| Patient No. | Age (yr) | Sex | Therapies |
ΔTSurvival | ΔTEFS | Time of DTI Studies (mo after initial diagnosis) | ||
|---|---|---|---|---|---|---|---|---|
| RT | Initial Post-RT Chemotherapy, Prerelapse | At Disease Progression | ||||||
| 1 | 10.6 | F | RT + CP/ETO | IRI + TEM + AVA | None | 12.6 | 6.8 | Bsl, 2.7, 5.9, 8.9,10.7 |
| 2 | 3.8 | M | RT + CP/ETO | IRI + TEM + AVA | None | 10.9 | 6.5 | Bsl, 1.9, 5.1 |
| 3 | 9 | M | RT + CP | None | None | 9.1 | 4.2 | Bsl, 3.3, 5.9 |
| 4a | 8.9 | M | RT + CP/ETO | IRI + TEM + AVA | AVA, Oral ETO | 15.4 | 8.3 | Bsl, 2.5, 9.8, 11.1, 13.3, 15.3 |
| 5 | 8.1 | F | RT + CP/ETO | IRI + TEM + AVA | None | 11.2 | 5.2 | Bsl, 2.6, 6.9 |
| 6 | 4.6 | F | RT + CP/ETO | IRI + TEM + AVA | AVA, Oral ETO | 19.1 | 12.6 | Bsl, 8.4, 14.2, 16.2 |
| 7 | 7.4 | F | RT + TEM/IRI | TEM/IRI | None | 12.4 | 9.6 | Bsl, 2.7, 6.8 |
| 8 | 9.5 | M | RT only | None | None | 6.4 | 4.3 | Bsl, 2.5, 4.3 |
| 9 | 7 | F | RT + TEM | TEM | Cyclophosphamide (Cytoxan) | 8.9 | 4.6 | Bsl, 5.3, 6.3 |
| 7.7 ± 2.2 | 5 F/4 M | 11.8 ± 3.8 | 6.9 ± 2.8 | 33 studies | ||||
a
Biopsy-confirmed anaplastic astrocytoma at presentation, glioblastoma at postmortem examination.